title: LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.
abstract: L-type amino acid transporter 1 (LAT1, SLC7A5) incorporates essential amino acids into cells. Recent studies have shown that LAT1 is a predominant transporter in various human cancers. However, the function of LAT1 in thymic carcinoma remains unknown. Here we demonstrate that LAT1 is a critical transporter for human thymic carcinoma cells. LAT1 was strongly expressed in human thymic carcinoma tissues. LAT1-specific inhibitor significantly suppressed leucine uptake and growth of Ty82 human thymic carcinoma cell lines, suggesting that thymic carcinoma takes advantage of LAT1 as a quality transporter and that LAT1-specific inhibitor might be clinically beneficial in therapy for thymic carcinoma.
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Keitaro
authors: K
authors: Hayashi
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Promsuk
authors: P
authors: Jutabha
authors: Department of General Thoracic Surgery, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Sumiko
authors: S
authors: Maeda
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Yothaisong
authors: Y
authors: Supak
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Motoshi
authors: M
authors: Ouchi
authors: J-Pharma Co., Ltd., Yokohama, Kanagawa 230-0046, Japan.
authors: Hitoshi
authors: H
authors: Endou
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Tomoe
authors: T
authors: Fujita
authors: Department of General Thoracic Surgery, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan.
authors: Masayuki
authors: M
authors: Chida
authors: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Tochigi 321-0293, Japan; Department of Pharmacology, Chiba University Graduate School of Medicine, Chuo, Chiba 260-8670, Japan. Electronic address: anzai-path@umin.ac.jp.
authors: Naohiko
authors: N
authors: Anzai
mesh_terms: D000596:Amino Acids / Q000378:metabolism*; D001583:Benzoxazoles / Q000494:pharmacology; D045744:Cell Line, Tumor; D006801:Humans; D027283:Large Neutral Amino Acid-Transporter 1 / Q000096:biosynthesis / Q000378:metabolism*; D007930:Leucine / Q000378:metabolism; D013945:Thymoma / Q000188:drug therapy / Q000378:metabolism*; D013953:Thymus Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C548172:2-amino-3-(4-((5-amino-2-phenylbenzo(d)oxazol-7-yl)methoxy)-3,5-dichlorophenyl)propanoic acid; D000596:Amino Acids; D001583:Benzoxazoles; D027283:Large Neutral Amino Acid-Transporter 1; D014443:Tyrosine; D007930:Leucine
keywords: Anticancer drug; Thymic carcinoma; Transporter